DelveInsight’s “Degenerative Disc Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Degenerative Disc Disease, historical and forecasted epidemiology as well as the Degenerative Disc Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Degenerative Disc Disease Market by downloading the comprehensive report from DelveInsight @ Degenerative Disc Disease Treatment Market Size
Key Takeaways from the Degenerative Disc Disease Market Report
- In October 2024:- Mesoblast Ltd-The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.
- In October 2024:- VIVEX Biologics Inc.- The study is a randomized, double-blind, sham-controlled, multi-center study in participants with symptomatic lumbar intervertebral disc degeneration (> 6 months) and unresponsive to conservative therapy for at least 3 months. Participants will be randomized on a 1:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or a sham procedure at 1 or 2 levels.
- DelveInsight’s epidemiology model estimates that there were approximately 73 million prevalent cases of Chronic Low Back Pain (CLBP) in the 7MM in 2023, with nearly 64 million diagnosed cases. This number is projected to rise throughout the forecast period (2024-2034).
- In 2023, the US had the highest number of diagnosed prevalent cases of DDD, with nearly 13 million cases. This figure is expected to rise by 2034.
- Among EU4 and the UK, the UK reported the highest number of diagnosed prevalent cases of DDD in 2023, with approximately 2.1 million cases. Germany closely followed with nearly 2 million cases, while Italy had the lowest at around 1 million.
- In 2023, the age-specific diagnosed prevalent cases of DDD in the 7MM showed notable trends: approximately 2.53 million cases for ages 18-29 years, 3.48 million for 30-39 years, 4.16 million for 40-49 years, and a peak of 5.14 million for 50-59 years. Cases were around 5.07 million in the 60-69 years group, 3.34 million for 70-79 years, and approximately 1.88 million for those aged 80 years and above.
- As per DelveInsight’s analysis, the US recorded approximately 32 million diagnosed prevalent cases of chronic low back pain (CLBP) in 2023. This number is expected to rise significantly during the forecast period from 2024 to 2034, driven by factors such as lifestyle changes, increasing obesity rates, and insufficient physical activity. These trends highlight the pressing need for targeted interventions aimed at addressing lifestyle-related issues to improve patient outcomes and reduce the burden of CLBP.
- The leading Degenerative Disc Disease Companies such as Mesoblast, Ltd., Grünenthal, DiscGenics, Inc., Spine Biopharma, Yuhan Corp, BioRestorative Therapies, AnGes, Inc., Shionogi & Co., Ltd., Kuros Biosurgery AG, Creative Medical Technology Holdings Inc., Stayble Therapeutics, Citospin, and others.
- Promising Degenerative Disc Disease Therapies such as Rexlemestrocel-L (MPC-06-ID), IDCT (Rebonuputemcel), SB-01 (Peniel2000/P2K, YH14618), BRTX-100, AMG0103 (NF-κB decoy oligonucleotide), and others.
Gain a competitive edge in the Degenerative Disc Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Degenerative Disc Disease Treatment Drugs
Degenerative Disc Disease Epidemiology Segmentation in the 7MM
- Total Degenerative Disc Disease Diagnosed Prevalent Cases
- Degenerative Disc Disease Gender-specific Diagnosed Prevalent Cases
- Degenerative Disc Disease Age-specific Diagnosed Prevalent Cases
Degenerative Disc Disease Market Insights
Degenerative Disc Disease (DDD) primarily impacts the intervertebral discs, which serve as shock absorbers between the vertebrae of the spine. With time, these discs may deteriorate, resulting in pain, stiffness, and overall discomfort. While DDD is a natural consequence of aging, factors such as genetics, smoking, and repetitive stress can expedite the degenerative process. The main objective in treating DDD is to alleviate symptoms, especially pain, enhance overall function, and halt further degeneration of the intervertebral discs. Although complete reversal of disc degeneration is unlikely, the emphasis is on improving the individual’s quality of life by reducing pain, increasing mobility, and maximizing spinal functionality. Treatment strategies typically involve a blend of non-pharmacologic interventions, lifestyle changes, and, in certain cases, surgical options, tailored to the severity and unique characteristics of each patient’s condition.
Discover key developments and opportunities in the Degenerative Disc Disease Market. Click here to learn more from DelveInsight’s latest report @ Degenerative Disc Disease Market Size
Degenerative Disc Disease Treatment Market Landscape
The Degenerative Disc Disease treatment market landscape is rapidly evolving, offering a spectrum of options from conservative measures like physical therapy and lifestyle changes to invasive procedures such as spinal fusion and artificial disc replacement. Recent advancements in minimally invasive techniques and regenerative medicine, including intradiscal pharmacologic treatments like Spine BioPharm’s SB-01, present promising alternatives that may fill the gap between conservative care and major surgery. However, significant unmet needs remain, especially concerning the long-term effectiveness of current treatments and the high costs associated with surgical interventions. There is an increasing demand for effective non-surgical options that can deliver lasting relief and enhance quality of life without the risks and expenses tied to traditional surgical methods. Addressing these gaps is essential for improving patient outcomes and satisfaction in DDD management.
Degenerative Disc Disease Emerging Therapies
- SB-01: Spine Biopharma
- Rexlemestrocel-L (MPC-06-ID): Mesoblast/Grünenthal
- IDCT (rebonuputemcel): DiscGenics
Degenerative Disc Disease Market Outlook
The primary treatment goal for DDD is to manage symptoms, particularly pain, improve overall function, and prevent further degeneration of the intervertebral discs. While complete reversal of disc degeneration may not be achievable, the focus is on enhancing the individual’s quality of life by minimizing pain, improving mobility, and optimizing the overall functionality of the spine. Treatment approaches often involve a combination of non-pharmacologic interventions, lifestyle modifications, and, in some cases, surgical options, depending on the severity and specific characteristics of the condition in each patient.
Download DelveInsight’s Degenerative Disc Disease Market report today and stay ahead in this rapidly evolving field. @ Degenerative Disc Disease Clinical Trials
Scope of the Degenerative Disc Disease Market Report
- Coverage- 7MM
- Degenerative Disc Disease Companies- Mesoblast, Ltd., Grünenthal, DiscGenics, Inc., Spine Biopharma, Yuhan Corp, BioRestorative Therapies, AnGes, Inc., Shionogi & Co., Ltd., Kuros Biosurgery AG, Creative Medical Technology Holdings Inc., Stayble Therapeutics, Citospin, and others.
- Degenerative Disc Disease Therapies- Rexlemestrocel-L (MPC-06-ID), IDCT (Rebonuputemcel), SB-01 (Peniel2000/P2K, YH14618), BRTX-100, AMG0103 (NF-κB decoy oligonucleotide), and others.
- Degenerative Disc Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Degenerative Disc Disease Unmet Needs, KOL’s views, Analyst’s views, Degenerative Disc Disease Market Access and Reimbursement
Download the report to understand which factors are driving Degenerative Disc Disease Market Trends @ Degenerative Disc Disease Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Degenerative Disc Disease (DDD) Market Overview at a Glance
4 Epidemiology and Market Methodology of DDD
5 Executive Summary of Degenerative Disc Disease (DDD)
6 Key Events
7 Degenerative Disc Disease (DDD) Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Emerging Therapies
11 DDD: Market Analysis
12 Key Opinion Leaders’ Views
13 SWOT Analysis
14 Unmet Needs
15 Market Access and Reimbursement
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/